Authors

Latest:

Steven Buechler Discusses EarlyR Gene Signature in the BIG 1-98 Trial for Breast Cancer

Steven Buechler, PhD, Department of Applied and Computational Mathematics and Statistics at the University of Notre Dame, discusses independent validation of the EarlyR gene signature in the Breast International Group (BIG) 1-98 study. This randomized, double-blind, phase III trial compared letrozole with tamoxifen as an adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer

Steven Campbell, MD, PhD

Latest:

Dr. Campbell Discusses the Goals of the New RCC Guidelines

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the goals of the newly updated guidelines in renal cell carcinoma.

Steven Coutre, MD

Latest:

Dr. Coutre Discusses Combination Strategies in ALL

Steven Coutre, MD, professor of medicine at Stanford University Medical Center, discusses combination strategies for the treatment of patients with acute lymphoblastic leukemia (ALL).

Steven Coutre, MD, Stanford University Medical Center

Latest:

Emerging Agents for R/R CLL

Experts discuss emerging agents for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

Steven D. Passik, PhD

Latest:

Clinician's View: Making Survival a Blessing, Not a Burden

More and more deadly diseases are slowly being transformed into chronic conditions. This is especially true of cancer.

Steven E. Finkelstein, MD

Latest:

Hypofractionated and Stereotactic Body Radiotherapy in Prostate Cancer

Despite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.

Steven Eric Finkelstein, MD

Latest:

Shooting for the Moon…and Beyond

This is an exciting time, as reports of major news impacting oncology research are emerging, it seems, on a daily basis.

Steven Eric Finkelstein, MD, FACRO

Latest:

Radiation Therapy, Chemotherapy, Targeted Therapy, and Possibly Immunotherapy in Localized Sarcoma

As clinicians have gained an improved understanding of the biology of soft-tissue sarcoma malignancies, the ability to better distinguish and identify subtypes has extended the hope of targeted treatment options.

Steven Eric Finkelstein MD PhD

Latest:

Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas

Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.

Steven Finkelstein, MD

Latest:

Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal Effects

The combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.

Steven H. Lin, MD, PhD

Latest:

Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC

Steven H. Lin, MD, PhD, discusses the safety of NKTR-255 in enhancing immune recovery post-chemoradiation in locally advanced NSCLC.

Steven Horwitz, MD

Latest:

Dr. Horwitz on Ongoing Trials in T-Cell Lymphoma

Steven Horwitz, MD, associate attending physician at Memorial Sloan Kettering Cancer Center, discusses some of the ongoing clinical trials being explored in T-cell lymphoma.

Steven I. Park, MD

Latest:

Dr. Park on Alisertib in Myc-Overexpressing Lymphoma Cells

Steven I. Park, MD, director, Lymphoma Program, associate professor of Medicine, Leukemia, Lymphoma, and Myeloma Program, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Clinical Research, discusses how alisertib induces synthetic lethality and overcomes chemoresistance in Myc-overexpressing lymphoma cells.

Steven I. Sherman, MD

Latest:

Dr. Sherman Defines RAI Resistance in Thyroid Cancer

Steven I. Sherman, MD, from the MD Anderson Cancer Center, describes the need to expand the clinical definition of radioactive iodine resistance for patients with thyroid cancer.

Steven I. Sherman, MD, MD Anderson

Steven J. DiBiase, MD

Latest:

Dr. DiBiase on Data With DM-CHOC-PEN/Radiation in Cancers Involving the CNS

Steven J. DiBiase, MD, chair and chief of service for the Julia and Ned Arnold Center for Radiation Oncology, NewYork-Presbyterian Queens, vice chairman and assistant interim professor of radiation oncology, Weill Cornell Medicine, discusses data with 4-demethyl-4 cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) plus radiation in cancers involving the central nervous system (CNS).

Steven J. Frank, MD

Latest:

Payers Manipulate Definition of Necessity

When it comes to health coverage, most Americans face an unnerving reality—they have no idea what is covered under their health insurance policy until they are affected by illness or disease.

Steven J. Katz, MD, MPH

Latest:

How Genetic Testing Impacts Breast Cancer Treatment Decisions

As genetic testing becomes increasingly available, there will be a growing gap between the wide availability of testing and the relative importance of results to treatment decisions.

Steven Katz, MD

Latest:

Dr. Katz on Precision Medicine in Breast Cancer

Steven Katz, MD, professor, Internal Medicine, University of Michigan Health System, discusses the incorporation of precision medicine into the treatment paradigm of breast cancer.

Steven M. Grunberg, MD

Latest:

Dr. Grunberg on Barriers to Effective Supportive Care

Steven M. Grunberg, MD, University of Vermont, on Barriers to Providing Effective Supportive Care for Patients with Cancer.